- In January 2024, Bone Therapeutics launched a Phase I/IIa clinical trial for its allogeneic cell therapy product, ALLOB, targeting patients with osteogenesis imperfecta. The trial aims to assess ALLOB's effectiveness in enhancing bone strength and minimizing the risk of fractures in individuals suffering from this condition. This initiative marks a significant step forward in the development of innovative therapeutic solutions for osteogenesis imperfecta, with the potential to improve patient outcomes
- In March 2023, Mereo BioPharma Group plc revealed encouraging topline results from its Phase 2b ASTER study, which focused on setrusumab, a novel anti-sclerostin antibody aimed at treating adults with osteogenesis imperfecta. The study demonstrated promising efficacy and safety outcomes, highlighting the potential of setrusumab as a therapeutic option for managing this rare bone disorder. These findings represent a significant advancement in the development of targeted treatments for individuals affected by osteogenesis imperfecta
- In July 2023, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company dedicated to developing innovative therapies, announced that the first patients have been treated in its late-stage clinical trials assessing setrusumab in pediatric and young adult patients with osteogenesis imperfecta sub-types I, III, and IV. The Phase 3 segment of the pivotal Phase 2/3 Orbit study is focused on comparing the effects of setrusumab versus placebo on the annualized clinical fracture rate in patients aged 5 to under 26 years. Additionally, the newly initiated Phase 3 Cosmic study is actively evaluating setrusumab against intravenous bisphosphonate therapy for its impact on the total fracture rate in patients aged 2 to under 5 years
- In October 2022, the Osteogenesis Imperfecta Federation Europe (OIFE) announced its re-establishment as a new legal entity in Belgium, marking a significant transition for the organization. This move involved dissolving its previous legal status in the Netherlands, streamlining its operations and governance structure. The reorganization aims to enhance the federation's effectiveness in advocating for individuals affected by osteogenesis imperfecta and to strengthen its commitment to improving patient support and awareness across Europe
- In October 2021, Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, collaborated with the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) to complete enrollment for the largest global data collection effort to date on the impact of osteogenesis imperfecta (OI) on affected individuals, their families, and caregivers. The IMPACT Survey gathered over 2,200 responses within a three-month timeframe from approximately 65 countries, highlighting the widespread relevance of the condition. The findings from this survey will inform future collaborative initiatives aimed at improving diagnosis, treatment, and care, as well as facilitating the timely evaluation and availability of new therapies for OI
Frequently Asked Questions
The market is segmented based on Segmentation, By Drug Class (Teriparatide, Denosumab, and Others), Route of Administration (Oral, Intravenous, and Subcutaneous), End User (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2031
.
The Global Osteogenesis Imperfecta Treatment Market size was valued at USD 722.80 USD Million in 2023.
The Global Osteogenesis Imperfecta Treatment Market is projected to grow at a CAGR of 2.4% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
